• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis.

作者信息

Villar M, Sotgiu G, D'Ambrosio L, Raymundo E, Fernandes L, Barbedo J, Diogo N, Lange C, Centis R, Migliori G B

出版信息

Eur Respir J. 2011 Sep;38(3):730-3. doi: 10.1183/09031936.00195210.

DOI:10.1183/09031936.00195210
PMID:21885418
Abstract
摘要

相似文献

1
Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis.利奈唑胺治疗耐多药和广泛耐药结核病的安全性、耐受性及疗效。
Eur Respir J. 2011 Sep;38(3):730-3. doi: 10.1183/09031936.00195210.
2
Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence.利奈唑胺治疗广泛耐药结核病：回顾性数据得到实验证据的证实。
Eur Respir J. 2013 Jul;42(1):288-90. doi: 10.1183/09031936.00191712.
3
Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India.利奈唑胺：一种有效的、安全的、廉价的药物，用于治疗印度耐多药结核病治疗失败的患者。
Eur Respir J. 2012 Apr;39(4):956-62. doi: 10.1183/09031936.00076811. Epub 2011 Sep 29.
4
Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains.利奈唑胺对多重耐药结核菌株的最低抑菌浓度较低。
Eur Respir J. 2015 Jan;45(1):285-7. doi: 10.1183/09031936.00084614.
5
Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains.利奈唑胺对多重耐药结核菌株的最低抑菌浓度较低。
Eur Respir J. 2015 Jan;45(1):287-9. doi: 10.1183/09031936.00135014.
6
On linezolid efficacy and tolerability.关于利奈唑胺的疗效和耐受性。
Eur Respir J. 2012 Mar;39(3):770-2. doi: 10.1183/09031936.00116011.
7
Linezolid in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: experience of a paediatric infectious diseases unit.利奈唑胺治疗儿童耐多药/广泛耐药结核病：一家儿童传染病科的经验
Scand J Infect Dis. 2011 Jul;43(6-7):556-9. doi: 10.3109/00365548.2011.564649. Epub 2011 Mar 10.
8
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.耐多药和广泛耐药结核病的最佳药物治疗。
Lancet Infect Dis. 2010 Sep;10(9):621-9. doi: 10.1016/S1473-3099(10)70139-0.
9
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.关于《每日300毫克利奈唑胺治疗难治性耐多药和广泛耐药结核病》的评论
J Antimicrob Chemother. 2009 Nov;64(5):1119; author reply 1119-20. doi: 10.1093/jac/dkp291. Epub 2009 Aug 8.
10
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.每日300毫克利奈唑胺剂量用于治疗难治性耐多药和广泛耐药结核病——作者回应
J Antimicrob Chemother. 2009 Nov;64(5):1119-20. doi: 10.1093/jac/dkp344. Epub 2009 Sep 10.

引用本文的文献

1
Design and Synthesis of the Linezolid Bioisosteres to Resolve the Serotonergic Toxicity Associated with Linezolid.利奈唑胺生物电子等排体的设计与合成以解决与利奈唑胺相关的5-羟色胺能毒性。
ACS Med Chem Lett. 2024 May 20;15(6):924-937. doi: 10.1021/acsmedchemlett.4c00114. eCollection 2024 Jun 13.
2
Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance in Shanghai, China.中国上海贝达喹啉、地拉曼尼、利奈唑胺、氯法齐明和卷曲霉素对耐药性的最低抑菌浓度分布
Infect Drug Resist. 2023 Dec 11;16:7587-7595. doi: 10.2147/IDR.S440711. eCollection 2023.
3
Clinical effectiveness and reliability of linezolid in the treatment of pulmonary tuberculosis complicated with severe pneumonia: a meta-analysis.
利奈唑胺治疗肺结核合并重症肺炎的临床疗效及可靠性：一项荟萃分析
Am J Transl Res. 2022 Nov 15;14(11):7622-7631. eCollection 2022.
4
Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial.强化结核病治疗以降低结核性脑膜炎合并 HIV 感染和未感染患者的死亡率（INTENSE-TBM）：一项 III 期随机对照试验的研究方案。
Trials. 2022 Nov 8;23(1):928. doi: 10.1186/s13063-022-06772-1.
5
and Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis.并且 恶唑烷酮候选药物 OTB-658 对结核分枝杆菌的活性。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0097421. doi: 10.1128/AAC.00974-21. Epub 2021 Aug 16.
6
Factors influencing the length of hospital stay during the intensive phase of multidrug-resistant tuberculosis treatment at Amhara regional state hospitals, Ethiopia: a retrospective follow up study.影响埃塞俄比亚阿姆哈拉州立医院耐多药结核病强化治疗阶段住院时间的因素：一项回顾性随访研究。
BMC Public Health. 2020 Aug 8;20(1):1217. doi: 10.1186/s12889-020-09324-x.
7
Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis.利奈唑胺在结核分枝杆菌感染的小鼠模型中的药效学相关性及其毒性。
J Infect Dis. 2021 Jun 4;223(11):1855-1864. doi: 10.1093/infdis/jiaa016.
8
Tuberculosis elimination: where are we now?结核病消除：我们现在在哪里？
Eur Respir Rev. 2018 Jun 13;27(148). doi: 10.1183/16000617.0035-2018. Print 2018 Jun 30.
9
Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.地拉曼尼与贝达喹啉治疗儿童耐多药和广泛耐药结核病：一项系统评价
J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16.
10
Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.贝达喹啉、德拉马尼、利奈唑胺、氯法齐明、莫西沙星和加替沙星对中国北京广泛耐药结核病的药敏性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00900-17. Print 2017 Oct.